STOCK TITAN

EcoPhage Appoints José Alfredo García to its Board Of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
EcoPhage (TRNLY), a leader in sustainable phage-based biopesticides, has appointed José Alfredo García to its Board of Directors. García brings extensive experience in global agribusiness, having held senior executive roles at Rovensa Group where he focused on biologicals portfolio development and commercial leadership. His prior decade-long experience at FMC Corporation involved leading regulatory, development, marketing, and commercial operations across Mexico, Central America, and the Caribbean. Currently launching Nuvelis, a platform connecting agricultural technologies with distributors, García joins EcoPhage at a crucial time as the company anticipates its first U.S. EPA approval and prepares for commercial rollout. EcoPhage, founded by the Trendlines Group and Bayer, specializes in developing bacteriophage-based solutions for bacterial plant diseases.
EcoPhage (TRNLY), leader nei biopesticidi sostenibili a base di faghi, ha nominato José Alfredo García nel suo Consiglio di Amministrazione. García porta con sé una vasta esperienza nel settore agroindustriale globale, avendo ricoperto ruoli dirigenziali presso Rovensa Group, dove si è concentrato sullo sviluppo del portafoglio di prodotti biologici e sulla leadership commerciale. La sua esperienza decennale presso FMC Corporation ha incluso la gestione di operazioni regolatorie, di sviluppo, marketing e commerciali in Messico, America Centrale e Caraibi. Attualmente impegnato nel lancio di Nuvelis, una piattaforma che connette tecnologie agricole con distributori, García entra in EcoPhage in un momento cruciale, mentre l’azienda si prepara alla prima approvazione da parte della EPA statunitense e al lancio commerciale. EcoPhage, fondata da Trendlines Group e Bayer, è specializzata nello sviluppo di soluzioni a base di batteriofagi per le malattie batteriche delle piante.
EcoPhage (TRNLY), líder en biopesticidas sostenibles basados en fagos, ha nombrado a José Alfredo García en su Junta Directiva. García aporta una amplia experiencia en agronegocios globales, habiendo ocupado cargos ejecutivos senior en Rovensa Group, donde se enfocó en el desarrollo del portafolio de biológicos y en el liderazgo comercial. Su experiencia de una década en FMC Corporation incluyó la gestión de operaciones regulatorias, desarrollo, marketing y comerciales en México, Centroamérica y el Caribe. Actualmente, está lanzando Nuvelis, una plataforma que conecta tecnologías agrícolas con distribuidores. García se une a EcoPhage en un momento clave, mientras la empresa anticipa la primera aprobación de la EPA de EE.UU. y se prepara para el lanzamiento comercial. EcoPhage, fundada por Trendlines Group y Bayer, se especializa en desarrollar soluciones basadas en bacteriófagos para enfermedades bacterianas en plantas.
EcoPhage(TRNLY)는 지속 가능한 파지 기반 생물농약 분야의 선두주자로, 호세 알프레도 가르시아를 이사회에 임명했습니다. 가르시아는 글로벌 농업 비즈니스에서 풍부한 경험을 보유하고 있으며, Rovensa Group에서 생물학적 제품 포트폴리오 개발 및 상업 리더십을 담당하는 고위 임원으로 근무했습니다. FMC Corporation에서는 멕시코, 중앙아메리카 및 카리브 지역에서 규제, 개발, 마케팅 및 상업 운영을 10년간 이끌었습니다. 현재 농업 기술과 유통업체를 연결하는 플랫폼인 Nuvelis를 출시 중인 가르시아는 EcoPhage가 미국 EPA의 첫 승인을 앞두고 상업 롤아웃을 준비하는 중요한 시점에 합류했습니다. Trendlines Group과 Bayer가 설립한 EcoPhage는 식물 세균성 질병을 위한 박테리오파지 기반 솔루션 개발을 전문으로 합니다.
EcoPhage (TRNLY), leader dans les biopesticides durables à base de bactériophages, a nommé José Alfredo García à son conseil d'administration. García apporte une vaste expérience dans l'agrobusiness mondial, ayant occupé des postes de direction chez Rovensa Group où il s'est concentré sur le développement du portefeuille de produits biologiques et la direction commerciale. Son expérience de dix ans chez FMC Corporation comprenait la gestion des opérations réglementaires, de développement, marketing et commerciales au Mexique, en Amérique centrale et dans les Caraïbes. Actuellement, il lance Nuvelis, une plateforme connectant les technologies agricoles aux distributeurs. García rejoint EcoPhage à un moment crucial, alors que l'entreprise anticipe sa première approbation par l'EPA américaine et prépare son déploiement commercial. Fondée par Trendlines Group et Bayer, EcoPhage se spécialise dans le développement de solutions à base de bactériophages pour les maladies bactériennes des plantes.
EcoPhage (TRNLY), ein führendes Unternehmen im Bereich nachhaltiger phagenbasierter Biopestizide, hat José Alfredo García in seinen Vorstand berufen. García bringt umfangreiche Erfahrung im globalen Agrargeschäft mit, nachdem er leitende Positionen bei Rovensa Group innehatte, wo er sich auf die Entwicklung biologischer Produktportfolios und die kommerzielle Führung konzentrierte. Seine zehnjährige Erfahrung bei FMC Corporation umfasste die Leitung von regulatorischen, Entwicklungs-, Marketing- und Vertriebsaktivitäten in Mexiko, Mittelamerika und der Karibik. Derzeit startet er Nuvelis, eine Plattform, die landwirtschaftliche Technologien mit Vertriebspartnern verbindet. García tritt EcoPhage zu einem entscheidenden Zeitpunkt bei, da das Unternehmen seine erste Zulassung durch die US-Umweltschutzbehörde EPA erwartet und sich auf die Markteinführung vorbereitet. EcoPhage, gegründet von der Trendlines Group und Bayer, spezialisiert sich auf die Entwicklung von bakterienphagenbasierten Lösungen für bakterielle Pflanzenkrankheiten.
Positive
  • Appointment of experienced agribusiness executive with global expertise in biologicals and commercial strategy
  • Company is expecting its first U.S. EPA approval
  • Strategic timing of appointment coincides with commercial rollout preparation
  • Board member brings direct experience in scaling biological solutions and market development
Negative
  • None.

OR YEHUDA, Israel, June 23, 2025 /PRNewswire/ -- EcoPhage, a leader in the development and commercialization of sustainable phage-based biopesticides for bacterial plant diseases, expecting its first U.S. EPA approval, is pleased to announce the appointment of Mr. José Alfredo García, to its Board of Directors. With extensive experience in building and scaling global agribusiness platforms, García joins at a pivotal time as the company prepares for commercial rollout in key markets

Mr. García held senior executive roles at Rovensa Group, where he contributed to the development of global strategies and the organizational consolidation of the company's biologicals portfolio. During his tenure, he was involved in commercial leadership and integration efforts across multiple geographies, with a strong focus on innovation, sustainable inputs, and growth initiatives in Latin America and Europe.

Prior to that, he spent more than a decade at FMC Corporation, where he led regulatory, development, marketing, and commercial operations across Mexico, Central America, and the Caribbean. This experience provided him with a strong technical foundation and a deep understanding of the industry, global distribution systems, and innovation dynamics in the agricultural inputs industry.

He is launching Nuvelis, a platform that aims to connect breakthrough agricultural technologies with leading distributors and manufacturers across key agricultural markets.

"I've witnessed firsthand how the agricultural inputs sector is evolving—from traditional chemistry to biological precision," said José Alfredo García. "From my early days at FMC, through my involvement in global biosolutions platforms, to now launching Nuvelis, I've always believed that innovation only matters when it's scalable. EcoPhage combines scientific excellence with real-world impact, and I'm honoured to contribute to its journey."

EcoPhage, founded by the Trendlines Group and Bayer, is at the forefront of developing next-generation bacteriophage-based solutions to combat bacterial plant diseases with minimal environmental impact.

"José Alfredo's deep expertise in commercial strategy, M&A integration, and market development makes him a powerful addition to our board," said Nitza Kardish, PhD, Chair of EcoPhage.

"He brings global perspective, operational discipline, and a true passion for biologicals—exactly what EcoPhage needs as we move into commercialization," added Guy Elitzur, CEO of EcoPhage.

About Trendlines

The Trendlines Group invests in innovation in agrifood and medtech, leveraging our experience, partnerships network, and resources to go from seed to market. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

About EcoPhage

EcoPhage pioneers the development and commercialization of bacteriophages-based bactericides with minimal environmental impact and maximum efficacy, addressing a crucial issue in global agriculture. Our innovative products harness the power of bacteriophages--viruses uniquely targeting bacteria--to prevent and cure plants, offering nontoxic solutions for bacterial diseases. For more information, please visit EcoPhage.com.

Our mission is to transform the agricultural bactericide market by offering precise, natural, and sustainable solutions to combat bacterial plant diseases. Co-developed with the prestigious Weizmann Institute of Science, EcoPhage's proprietary technology platform enables safer and more effective crop protection, helping farmers increase yields and reduce losses while promoting ecological balance.

Media Contact:
Email: info@ecophage.com

Cision View original content:https://www.prnewswire.com/news-releases/ecophage-appoints-jose-alfredo-garcia-to-its-board-of-directors-302488277.html

SOURCE EcoPhage

FAQ

Who is José Alfredo García and why was he appointed to EcoPhage's (TRNLY) board?

José Alfredo García is an experienced agribusiness executive who previously held senior roles at Rovensa Group and FMC Corporation. He was appointed to EcoPhage's board for his expertise in scaling global agribusiness platforms and experience in biological solutions as the company prepares for commercial rollout.

What is EcoPhage's (TRNLY) main business focus?

EcoPhage develops and commercializes sustainable phage-based biopesticides for bacterial plant diseases, focusing on next-generation bacteriophage-based solutions with minimal environmental impact.

When is EcoPhage (TRNLY) expecting its first EPA approval?

While the exact date isn't specified in the press release, EcoPhage is currently expecting its first U.S. EPA approval as mentioned in conjunction with their commercial rollout preparations.

Who are the founding companies of EcoPhage (TRNLY)?

EcoPhage was founded by the Trendlines Group and Bayer.

What is Nuvelis and how is it related to EcoPhage's (TRNLY) new board member?

Nuvelis is a platform being launched by José Alfredo García that connects breakthrough agricultural technologies with leading distributors and manufacturers across key agricultural markets.
Trendlines Group

OTC:TRNLY

TRNLY Rankings

TRNLY Latest News

TRNLY Stock Data

38.22M
452.01M
Asset Management
Financial Services
Link
Israel
M P Misgav